

HORUN)) ((``__((

PRESENTING INNOVATIVE PRODUCTS & SERVICES TO HEALTHCARE PROFESSIONALS

VOLUME 13 NUMBER 3 MARCH 2006 REPRINT

UNIQUE AMLACTIN® XL® IS A CLINICALLY **PROVEN SUPERIOR MOISTURIZER** (1)

ry skin (xerosis) is a common problem, especially as people get older. Many factors are responsible for dry skin, such as cold, dry weather and frequent bathing, which cleanses the skin of essential moisture-retaining oils. Treating dry skin requires an effective product that can hold moisture in the skin.

AmLactin[®] XL[®] Alleviates Dry Skin With Its Unique UltraPlex[™] Formulation

AmLactin[®] XL[®] UltraPlex[™]

formulation is composed of a proprietary blend of moisturizing compounds (containing ammonium/potassium/sodium lactate lotion), a naturally occurring alpha-hydroxy acid, and humectant that helps skin to better retain moisture. Am-Lactin[®] XL[®] can be used on almost all areas of the body (but should not be applied to lips and mucous membranes), and is especially helpful in treating rough, dry, and cracked areas such as calluses on the feet. In fact, the American Podiatric Medical Association

recommends AmLactin® XL® for treating calluses and corns (2).

Clinical Study Shows Superiority of AmLactin[®] XL[®]

A recent study compared AmLactin® XL® with 40% urea cream in 26 healthy women with moderate-to-severe dry skin of the

FRAGRANCE FREE mLactin MOISTURIZING LOTIO 160 g (5.6 oz)

lower legs (1). The study randomized participants to apply one of the products to the right or left leg twice daily for 21 days, followed by a 21-day regression period. An expert grader evaluation of visual dryness and tactile roughness was conducted at baseline and days 7, 14, and 21 of the treatment and regression periods; the participants also completed self-assessment questionnaires and a product satisfaction questionnaire.

AmLactin[®] XL[®] was significantly more effective at improving visual dryness and tactile roughness after 7 days of treatment (p <0.0001), with significance persisting through regression day 14. Net change from baseline in visual dryness and tactile roughness also was significantly greater for AmLactin® XL® on treatment days 7, 14, and 21. Participants judged AmLactin® XL[®] to be statistically superior in improving skin dryness on treatment days 7, 14, and 21, and regression days 3 and 7; and for smoothness, softness, and texture on treatment days 14 and 21 and regression days 3

and 7 (p < 0.05). Net changes from baseline for self-assessment endpoints were all significantly better for AmLactin® XL® on treatment days 7, 14, and 21, except for dryness, which was significant only on days 14 and 21. Overall, participants rated AmLactin® XL® more effective in moisturizing moderate-to-severe dry skin, and had significantly higher overall satisfaction with

AmLactin[®] XL[®] on treatment day 21 and regression day 21.

The winter season is notorious for causing dry, itchy skin, because of lower temperatures and drier air, which contribute to more moisture loss from the skin. Dermatologist Ellen Blank, MD, of Mt. Sinai Hospital (New York, NY), recommends AmLactin[®] XL[®] to many of her patients.

"It's an excellent product that really solves the problem of dry skin," Dr. Blank said, adding, "I've had a lot of patients with consistently dry skin and they rave about AmLactin[®] XL[®]."

J. Hunter Phillips, MD, FACP, Clinical Assistant Professor at Tulane University (New Orleans, LA), also recommends AmLactin[®] XL[®] for many patients in his practice. "With its unique Ultra-Plex[™] formulation, it is very effective for almost all cases of severely dry or irritated skin," he said. "Everybody to whom I've recommended AmLactin[®] XL[®] has been extremely happy. It's a great moisturizer—I use it too."

AmLactin[®] XL[®]'s superior hydrating properties (including skin surface hydration and water binding capacity) have been proven clinically to be significantly more effective in moisturizing rough, dry skin (1). AmLactin[®] XL[®] is a fragrance-free, high-potency alpha hydroxy dry skin therapy that can be applied to affected areas twice daily. "I particularly like it because of the triple combination of the lactic acid salts and the fact that it is fragrance free," added Dr. Phillips.

Upsher-Smith Laboratories' Am-Lactin[®] line of skin care products has been awarded the American Podiatric Medical Association's Seal of Approval, which recognizes products that benefit foot health and are of significant value when used in a consistently applied program of daily foot care and regular professional treatment (3). Upsher-Smith's family of AmLactin® products is among the most frequently recommended moisturizers, according to a 2005 survey published in Dermatology Times (3). In 2004, Upsher-Smith added Am-Lactin® XL® to its line of superior moisturizing products.

About Upsher-Smith:

Upsher-Smith Laboratories, Inc. is a fully integrated pharmaceutical company that manufactures and markets prescription pharmaceutical, OTC, and cosmetic products. Upsher-Smith is also actively involved in licensing innovative compounds that are in clinical development.



For more information concerning Upsher-Smith Laboratories, Inc., write to Upsher-Smith Laboratories, Inc., 6701 Evenstad Drive, Maple Grove, MN 55369; call 1-800-654-2299; or visit the company's Web site at www.upsher-smith.com

References:

- 1. Data on file, Upsher-Smith Laboratories, Inc.
- Technology for the Soles. American Podiatric Medical Association. Available at: www.apma.org/s_apma/ bin.asp?TrackID=&SID=1&DID =19152&CID=253&VID=2&DOC =File.PDF. Accessed Feb. 9, 2006.
- Dry skin; most recommended moisturizing product. Omnibus Study, *Dermatology Times*, 2005:71.

Medco Forum* is a registered trademark of Medco Communications LLC. Copyright © 2006 Medco Communications LLC. On editorial matters or to request additional copies, telephone (303) 674-9607. Any reproduction, in whole or in part, without express written permission of publisher is prohibited. The information and statements directed to the products discussed herein are based solely on information and statements received from manufacturers and/or distributors thereof. The publishers do not warrant and assume no liability for the accuracy of the information contained herein. The manufacturers and/or distributors thereof. The publishers. Send inquiries or comments regarding this publication to: Medco Communications LLC, 87 Oak Way, Evergreen, CO 80439.